GENERAL GUIDANCE FOR INSPECTORS
ON “HOLD-TIME” STUDIES

REVISED DRAFT FOR COMMENT

Should you have any comments on the attached text, please send these to
Dr Sabine Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance
and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland;
e-mail: kopps@who.int; fax: (+41 22) 791 4730 (kopps@who.int) and to
Ms Marie Gaspard (gaspardm@who.int), by 15 September 2013.

Working documents are sent out electronically and they will also be placed on the
Medicines web site for comment. If you do not already receive directly our draft
guidelines please let us have your e-mail address (to bonnyw@who.int) and we will
add it to our electronic mailing list.

© World Health Organization 2013

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The
draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in
whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned
staff and member organizations) without the permission of the World Health Organization. The draft should not be
displayed on any web site.

Please send any request for permission to:
Dr Matthias Stahl, Prequalification of Medicines Programme, Medicines Quality Assurance Programme, Quality
Assurance and Safety: Medicines, Department of Essential Medicines and Pharmaceutical Policies, World Health
Organization, CH-1211 Geneva 27, Switzerland; e-mail: stahlm@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion
whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or
area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent
approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or
recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in
this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied.
The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health
Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
<table>
<thead>
<tr>
<th>Activity Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparation of draft by Dr A.J. van Zyl, South Africa, based on need identified by the WHO Prequalification Programme inspectors</td>
<td>November-December 2012</td>
</tr>
<tr>
<td>Preliminary internal review of draft</td>
<td>January 2013</td>
</tr>
<tr>
<td>Draft mailed for comments</td>
<td>February 2013</td>
</tr>
<tr>
<td>Collation of comments</td>
<td>April 2013</td>
</tr>
<tr>
<td>Review by inspectors collaborating with the WHO Prequalification Programme</td>
<td>May 2013</td>
</tr>
<tr>
<td>Discussion during the joint informal consultation with Prequalification Inspection team and inspectors from national inspectorates</td>
<td>30 May 2013</td>
</tr>
<tr>
<td>Follow-up of e-Discussion of Subgroup with expert inspectors to finalize new draft of working document for comments</td>
<td>June 2013</td>
</tr>
<tr>
<td>Recirculation of working document for comments</td>
<td>July 2013</td>
</tr>
<tr>
<td>Compilation of comments and feedback</td>
<td>September 2013</td>
</tr>
<tr>
<td>Review of feedback received with Prequalification Inspection team</td>
<td>September 2013</td>
</tr>
<tr>
<td>Presentation to forty-eighth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations</td>
<td>14-18 October 2013</td>
</tr>
<tr>
<td>Further follow-up action as required</td>
<td>…</td>
</tr>
</tbody>
</table>
Manufacturers should ensure that the products that they manufacture are safe, effective and of the quality required for their intended use. Products should be consistently manufactured to the quality standards appropriate to their intended use and as required by the marketing authorization. Systems should ensure that pharmaceutical products are produced according to validated processes and to defined procedures. Manufacturing processes should be shown to be capable of consistently manufacturing pharmaceutical products of the required quality that comply with their specifications.

Arrangements should exist to ensure that the dispensed starting and packaging materials used, intermediate products, bulk and finished products are stored under appropriate conditions. Storage should not have any negative effect on the processing, stability, safety, efficacy or quality of the materials, intermediate products and bulk products prior to final packing. Good manufacturing practices require that the maximum allowable hold time should be established to ensure that in-process and bulk product can be held, pending the next processing step, without any adverse effect to the quality of the material. These time periods must be supported by adequate data to demonstrate that the product will be stable throughout the approved shelf-life.

Normally intermediate and bulk products should not be stored for extended periods of time and are tested with stability-indicating methods.
83 **Scope**

84 This document does not intend to prescribe a process for establishing hold times, but reflects aspects that should be considered in the design of the hold-time study.

87 Manufacturers should gather scientific and justifiable data to demonstrate that the dispensed starting and packaging materials, intermediate and bulk products:

90 - remain stable before processing to the next stage;

92 - meet the acceptance criteria and stability specification for the finished product.

94 The quality and stability of starting materials, intermediate products, bulk and finished products should be ensured at all stages of manufacture.

98 Maximum allowable hold times should therefore be established for starting materials, intermediate products, bulk and finished products on the basis of tests related to storage conditions. Data to justify the hold time can be collected during development on pilot scale batches, during process validation, or as part of the investigation that occurred during manufacture.

104 Hold-time studies establish the time limits of holding the materials at different stages of production by assuring that the quality of the product does not deteriorate during the hold time. To validate the hold time under the specified hold-time condition, results obtained should be within the limits of acceptance criteria throughout the hold time. Hold times should normally be determined prior to marketing of a product and following any significant changes in processes, equipment, starting and packaging materials. For products already marketed hold-time studies should be performed.
Manufacturers may use a flow chart to review the manufacturing procedure of a product and then break up the critical stages of manufacturing process on the basis of time duration required for the particular processing stage and the impact of time period with reference to environmental conditions and storage conditions.

Generally, as an example for oral tablets, the following stages should be considered:

- binder preparation to granulation;
- wet granulation to drying;
- dried granules to lubrication/blending;
- lubrication/blending to compression;
- compression to coating;
- coating solution preparation to coating;
- coating to packing.

A written protocol, procedure or programme should be followed which includes the activities to be performed, test parameters and acceptance criteria appropriate to the material or product under test. The protocol and report should include but not be limited to the following: a title, reference number, version, date, objective, scope, responsibility, procedure, description of the material/product, sample quantities, sampling method and criteria, acceptance limits, frequency for sampling, sampling locations, pooling of samples, storage conditions, type of container, methods of analysis, results, conclusion, recommendation, signatures, dates

For certain products microbiological aspects should also be considered and included where appropriate.

Typically one or more batches of a material, intermediate or product can be used for determining hold times. A risk-based approach can be used to determine the appropriate number of batches. A representative sample of the batch of material or product subjected
to the hold-time study should be held for the defined hold period. The maximum storage
period for each category of material should be established on the basis of the study by
keeping the material in either the originator or simulated container used in production.
The containers used in which hold-time samples are stored should be of the same material
of construction as those used in manufacturing/quarantine. Hold-time samples should
have head space in proportion to bulk stored in manufacturing/quarantine. The sample
storage environmental conditions should be same as that of the quarantine
area/manufacture stage. *(Note: Where appropriate, a sampling plan should be established
and followed for taking samples for testing at the different intervals. The required sample
amount should be calculated based on the batch size, the intervals and tests to be
performed.)* At the test points a sample should be taken from the storage container and
tested. Results obtained should be compared with the initial baseline data of the control
sample results. Samples may be pooled for analysis where appropriate. Where necessary,
individual samples may be tested and compared statistically. Statistical calculations
should be done and trends identified and discussed to prove a reliable hold time.

Batches of products subjected to a hold-time study should also be subjected to long-term
stability testing.

In general the following table provides examples of generally accepted hold times for
materials, intermediate, bulk or finished products packed and stored in suitable
containers, based on product knowledge. However, specific cases may necessitate other
storage periods based on data.
Table 1. Example of maximum storage times without hold-time data

<table>
<thead>
<tr>
<th>Stage</th>
<th>Suggested maximum storage period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dispensed materials storage</td>
<td>5 to 30 days¹</td>
</tr>
<tr>
<td>Solutions prepared</td>
<td>8 to 24 hours</td>
</tr>
<tr>
<td>(including granulating pastes, coating</td>
<td></td>
</tr>
<tr>
<td>solutions and coating suspensions)</td>
<td></td>
</tr>
<tr>
<td>Granules</td>
<td>2 to 30 days²</td>
</tr>
<tr>
<td>Blend</td>
<td>1 to 2 days</td>
</tr>
<tr>
<td>Core tablets – uncoated (in bulk containers)</td>
<td>30 days</td>
</tr>
<tr>
<td>Coated tablets (in bulk containers)</td>
<td>30 days</td>
</tr>
</tbody>
</table>

Hold times should be established where materials, intermediate, bulk or finished products are stored for extended periods. Risk assessment (product specific) may further assist manufacturers to determine which stage, tests, intervals and storage periods should be considered for a hold time study. The accumulated hold time should be scientifically justified. Table 2 below provides examples of stages and tests that may be considered.

Table 2. Examples of stages and tests that may be considered, based on risk assessment and specific product needs

<table>
<thead>
<tr>
<th>Stage</th>
<th>Examples of tests to be considered³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dispensed materials storage</td>
<td>Microbial test</td>
</tr>
<tr>
<td>Solutions prepared</td>
<td>Physical appearance</td>
</tr>
<tr>
<td>(including granulating pastes, coating</td>
<td>Specific gravity</td>
</tr>
<tr>
<td>solutions and coating suspensions)</td>
<td>Viscosity</td>
</tr>
<tr>
<td></td>
<td>Sedimentation</td>
</tr>
<tr>
<td></td>
<td>pH</td>
</tr>
<tr>
<td></td>
<td>Microbial test</td>
</tr>
</tbody>
</table>

¹ Dispensed materials stored in containers similar to those in which material was supplied from the original manufacturer and under the same controlled conditions.
² Appropriate to the formulation of the granule.
³ These parameters are examples. Manufacturers have to identify and justify the selection of stages and parameters selected or excluded from a hold-time study.
| Granules | Description | Assay  
|----------|-------------|-------
|          | Moisture content (loss on drying) | Water content  
|          | Particle size distribution | Bulk density  
|          | Tap density | Angle of repose  
| Blend    | Microbial test | Moisture content (loss on drying)  
|          | Blend uniformity | Particle size  
|          | Bulk/tapped density |  
| Core tablets – uncoated (In bulk containers) | Description | Hardness  
|          | Thickness | Friability  
|          | Appearance | Dissolution  
|          | Disintegration | Assay  
|          | Degradation products/related substances | Uniformity of dosage units  
|          | (where applicable) | Microbial test  
| Coated tablets (in bulk containers) | Description | Hardness  
|          | Thickness | Friability  
|          | Appearance | Dissolution/dissolution profile  
|          | Disintegration | Assay  
|          | Degradation products/related substances | Uniformity of dosage units  
|          | (where applicable) | Moisture content  
|          | Microbial test |  

Hold-time data under specified conditions should demonstrate comparable stability to the dosage form in the marketed package.